Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2026 | Enhancing radiotherapy in melanoma with NBTXR3, a novel radioenhancer

Jason Chan, MD, University of California, San Francisco, CA, comments on the potential of NBTXR3, a first-in-class radioenhancer, in combination with radiation therapy for the treatment of melanoma, a tumor type known for its resistance to radiation. Dr Chan highlights the appeal of using a radioenhancer to enhance the effectiveness of radiation in melanoma, as well as its potential to elicit anti-tumor immunity and resensitize patients to anti-PD-1 therapy after progression on immunotherapy. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

NBTX R3 is a first-in-class radioenhancer. And the background for this particular study is that in melanoma, melanoma has a reputation of being a tumor that is resistant to radiation. So using a radioenhancer with radiation is appealing. And also finding effective treatments for melanoma patients who have progressed on immunotherapy is a great challenge. And so we were also seeing if the combination of the radioenhancer and radiation could elicit anti-tumor immunity and resensitize patients to anti-PD-1 therapy...

NBTX R3 is a first-in-class radioenhancer. And the background for this particular study is that in melanoma, melanoma has a reputation of being a tumor that is resistant to radiation. So using a radioenhancer with radiation is appealing. And also finding effective treatments for melanoma patients who have progressed on immunotherapy is a great challenge. And so we were also seeing if the combination of the radioenhancer and radiation could elicit anti-tumor immunity and resensitize patients to anti-PD-1 therapy.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.